Eli Lilly's obesity drug sales rise in India, Bloomberg reports
Eli Lilly (LLY) increased its sale of Mounjaro, its weight-loss and diabetes drug, by 60% in India in May from April, Satviki Sanjay of Bloomberg reports. The company sold $1.5M worth of injections last month, Bloomberg said, citing market analysis firm Pharmarack Technologies. 'The patient number may have actually doubled' in May from April Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is rising gradually and is expected to continue.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Keep the Portfolio Tilt Toward Risk, Lombard Odier's Lee Says
Lombard Odier's Homin Lee says investors should "keep the portfolio tilt toward risk" as latest developments suggest that "we're still in the middle of the deal making phase in the Trumpian trade policy." Lee discusses his outlook for global equities on Bloomberg Television. (Source: Bloomberg)
Bloomberg
2 hours ago
- Bloomberg
South Korea's Retail Investors Push for Change Among Corporate Laggards
South Korea's small investors are trying to shake up the country's creaky corporate landscape. Gathering on social media platform like KakaoTalk and dedicated shareholder apps, their aim is to give a jolt to Korea's famously undervalued stock market. Bloomberg TV's Shery Ahn explains. (Source: Bloomberg)
Yahoo
6 hours ago
- Yahoo
What to Expect From US, China Trade Talks Monday?
Mary Lovely, Senior Fellow at the Peterson Institute for International Economics, shares her thoughts on what to expect Monday as US and Chinese negotiators will resume trade talks in London. She also talks about the Trump tariffs and the impact the tariffs may have on the labor market if trade talks between the US and China do not go well. Mary Lovely speaks with Kailey Leinz and Joe Mathieu on the late edition of Bloomberg's "Balance of Power."
